Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability and Efficacy Study of PP1420 in HV

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Healthy male as determined by a responsible physician, based on a medical evaluation including history, physical examination, vital signs, laboratory tests and 12-lead ECG.~2. Between 18 and 50 years of age, inclusive, at the time of signing and dating the informed consent form.~3. Body weight 70 kg and body mass index (BMI) within the range 25 - 35 kg/m2 (inclusive).~4. Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.~5. Willing and able to comply with the protocol for the duration of the study.~Exclusion Criteria:~1. As a result of the medical interview, physical examination, or screening investigations, the Investigator considers the subject unsuitable for the study.~2. The subject has a positive pre-study drug/alcohol screen. A minimum list of drugs that will be screened for include amphetamines, barbiturates, cocaine, opiates, cannabinoids and benzodiazepines.~3. A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result within 3 months of screening.~4. A positive test for human immunodeficiency virus (HIV) antibody.~5. History of migraine.~6. History or evidence of abnormal eating behaviour, as observed through the Dutch Eating Behaviour (DEBQ) and SCOFF questionnaires.~7. History of excessive alcohol consumption within 6 months of the study defined as an average weekly intake of greater than 21 units or an average daily intake of greater than 3 units. One unit is equivalent to 8 g of alcohol, a half-pint (approximately 240 mL) of beer or 1 measure (25 mL) of spirits or 1 glass (125 mL) of wine.~8. Urinary cotinine levels indicative of smoking or history or regular use of tobacco- or nicotine-containing products within 6 months prior to screening.~9. Has QTc at screening \>450 msec.~10. Systolic blood pressure outside the range 85 - 160 mmHg, diastolic blood pressure outside the range 45 - 100 mmHg, and/or heart rate outside the range 40 - 110 bpm.~11. The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the dosing day in the current study: 90 days, five half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).~12. Exposure to more than four new chemical entities within 12 months prior to the first dosing day.~13. Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements within 14 days or five half-lives (whichever is longer) prior to the dose of study medication, which, in the opinion of the Investigator, may interfere with the study procedures or compromise subject safety.~14. History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the Investigator, contraindicates their participation.~15. Where participation in the study would result in donation of blood in excess of 500 mL within 3 months before or after the study.~16. Unwilling to abstain from:~    * Consumption of caffeine- or xanthine- containing products for 24 hours prior to dosing until the post-dose assessment at each treatment level.~   * Use of illicit drugs.~   * Alcohol for 48 hours prior to dosing until final post-dose assessment at each treatment level.~   * Smoking or otherwise consuming tobacco for 24 hours prior to dosing until the post-dose assessment at each treatment level.~17. Unwilling or unable to use a condom during sexual activity from first dose until the end of the study.~18. Vegans and subjects with milk or wheat intolerance or allergy as reported by the subject.~19. Unwillingness or inability to follow the procedures outlined in the protocol.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): Visit 1 - sham visit: placebo 0.9% (w/v) saline single-dose, administered subcutaneously.~Visit: 2 - placebo 0.9% (w/v) saline single-dose, administered subcutaneously.~Visit 3 - single dose of PP 1420, administered subcutaneously. Dose levels: 8, 16, 32, 64 mg.
- Arm 2 (Type: EXPERIMENTAL): Visit 1 - sham visit: placebo 0.9% (w/v) saline single-dose, administered subcutaneously.~Visit: 2 - single dose of PP 1420, administered subcutaneously. Dose levels: 8, 16, 32, 64 mg.~Visit 3 - placebo 0.9% (w/v) saline single-dose, administered subcutaneously.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues